SDDS 2025: Stanford Drug Discovery Symposium
Join us for the 2025 Stanford Drug Discovery Symposium! SDDS 2025 will be a cornerstone in the drug discovery community for networking and collaboration.
Related Articles
Bioadaptor may flatten event curve after PCI, including in complex lesions
WASHINGTON — A bioadaptor implant adaptable to vessel physiology was linked to fewer target lesion failure events after 6 months compared with a drug-eluting stent,…
Center for Molecular Cardiology Grand Rounds Webinar – P. J. Schwartz | ZHH
The Zurich Heart House creates and communicates new knowledge in the field of cardiovascular diseases. Through its affiliation with the University of Zurich, the editorial…
The role of maintaining lower LDL-C level during statin treatment for advanced CKD patients
Different from other high cardiovascular (CV) risks populations, the evidence supporting the CV protective effect of LDL-C reduction with statins in chronic kidney disease (CKD)…
🙏सुंदर कांड दोहा २८ (अर्थ सहित)🙏जय बजरंग बली🙏जय श्रीराम
🙏सुंदर कांड दोहा २८ (अर्थ सहित)🙏जय बजरंग बली🙏जय श्रीराम
Hypertrophic cardiomyopathy evolving management: American Heart Association/American College of Cardiology vs. European Society of Cardiology guidelines
The availability of cardiac myosin inhibitors (CMI) to treat symptomatic left ventricular outflow tract obstruction (LVOTO) and the evolving recommendation
Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival
AbstractBackground and Aims. The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomiz
Pediheart Podcast #318: Is It Time To Abolish The Insurance “Pre-Authorization” For Congenital Cardiology?
This week we review a recent thought-provoking work on the topic of the dreaded ‘pre-authorization’ process for procedures being performed in the US. Are there…
Dean of Weill Cornell Medicine Dr. Robert Harrington to receive the 2024 Chairman’s Award
Embargoed until 7 a.m. CT/8 a.m. ET, Wednesday, Nov. 6, 2024 DALLAS, Nov. 6, 2024 — Robert A. Harrington, M.D., FAHA, the Stephen and Suzanne…
New Blood Pressure Target For Individuals at High Risk – American College of Cardiology
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood…
